Commonwealth Biotech set to acquire Mimotopes
Register for free to listen to this article
Listen with Speechify
0:00
5:00
STORY UPDATE
RICHMOND, Va.—February 12, 2007—Commonwealth Biotechnologies Inc. (CBI) announced it has completed its acquisition of all outstanding capital stock of Mimotopes Pty. In the process, Mimotopes' former Executive Director Dr. Paul D'Sylva was installed as CEO and board member of the combined company.
RICHMOND, Va.—In a move seen as the initial step in a strategic repositioning of the company, Commonwealth Biotechnologies Inc. (CBI), a life sciences contract research organization and biotechnology company, has executed an agreement to acquire all of the outstanding capital stock of Mimotopes Pty. Ltd. Mimotopes, which is based in Melbourne, Australia, is a wholly owned subsidiary of PharmAust Chemistry Ltd. which is, in turn, a wholly owned subsidiary of PharmAust Limited.
Mimotopes is focused on the growing market for research-grade peptides and peptide therapeutics, a market estimated to grow at 40 percent per year over the next several years. Currently, peptide technologies make up about 3 percent of CBI's revenues. The acquisition of Mimotopes would represent an immediate boost in this revenue line, potentially making peptide technologies the source of 30 percent of CBI's revenues. If completed, this transaction will represent the single largest growth transaction in CBI's 15-year history.
In addition, CBI will acquire a sales team that is said to be well-versed in selling services to the pharmaceutical and biotech industry. Mimotopes currently has U.S.-based sales offices in San Diego, Minneapolis, and Raleigh, N.C., as well as offices in the United Kingdom and Melbourne. In addition to long-standing client relationships built over its nearly 20-year history, Mimotopes also brings to the table key partnerships with two major biotech and pharmaceutical entities—Invitrogen Corp. and Genzyme Pharmaceuticals—partnerships which CBI expects to foster and expand. CBI also expects new market opportunities in Australia and the Pacific Rim to result from this acquisition.
"The Mimotopes' client base and sales efforts are almost exclusively in the commercial sector, a market segment that CBI management is focused on developing as a key building block for the company's long-term growth strategy," according to Dr. Richard J. Freer, chairman and COO of CBI.
"The sale of Mimotopes to CBI will bring Mimotopes closer to its key clients and partners and facilitate its continued expansion in the USA," adds Dr. Paul D'Sylva, managing director of PharmAust Limited, who will become CEO of the combined entity. "Mimotopes and CBI offer complimentary drug discovery products and services, which when combined will deliver measurable revenue and cost synergies and create a stronger, more profitable business."